Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)

Detalles Bibliográficos
Autores principales: Mahajan, Kunal, Gaur, Naresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Diabetes India. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245264/
https://www.ncbi.nlm.nih.gov/pubmed/32473902
http://dx.doi.org/10.1016/j.dsx.2020.05.029
_version_ 1783537721137954816
author Mahajan, Kunal
Gaur, Naresh
author_facet Mahajan, Kunal
Gaur, Naresh
author_sort Mahajan, Kunal
collection PubMed
description
format Online
Article
Text
id pubmed-7245264
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Diabetes India. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72452642020-05-26 Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) Mahajan, Kunal Gaur, Naresh Diabetes Metab Syndr Article Diabetes India. Published by Elsevier Ltd. 2020 2020-05-23 /pmc/articles/PMC7245264/ /pubmed/32473902 http://dx.doi.org/10.1016/j.dsx.2020.05.029 Text en © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mahajan, Kunal
Gaur, Naresh
Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
title Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
title_full Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
title_fullStr Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
title_full_unstemmed Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
title_short Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
title_sort letter in response to the article: comorbidities in covid-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (singh et al.)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245264/
https://www.ncbi.nlm.nih.gov/pubmed/32473902
http://dx.doi.org/10.1016/j.dsx.2020.05.029
work_keys_str_mv AT mahajankunal letterinresponsetothearticlecomorbiditiesincovid19outcomesinhypertensivecohortandcontroversieswithreninangiotensinsystemblockerssinghetal
AT gaurnaresh letterinresponsetothearticlecomorbiditiesincovid19outcomesinhypertensivecohortandcontroversieswithreninangiotensinsystemblockerssinghetal

Ejemplares similares